Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.
Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Gupta R, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, Nguyen-Van-Tam JS, Norman L, Noursadeghi M, Olliaro PL, Pritchard MG, Russell CD, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LC, Openshaw PJ, Baillie JK, Semple MG, Docherty AB, Harrison EM, ISARIC4C investigators. · 2020
Read Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. by Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Gupta R, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, Nguyen-Van-Tam JS, Norman L, Noursadeghi M, Olliaro PL, Pritchard MG, Russell CD, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LC, Openshaw PJ, Baillie JK, Semple MG, Docherty AB, Harrison EM, ISARIC4C investigators. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7116472.txt.
Introduction
Knight and co-authors built and validated the 4C Mortality Score, a simple tool for judging death risk in patients admitted to hospital with COVID-19, in The BMJ. The score came from a prospective study across 260 hospitals in England, Scotland, and Wales. The training set held 35,463 patients and the validation set 22,361.
Eight items available at admission feed the score: age, sex, number of other illnesses, breathing rate, blood oxygen, consciousness level, urea, and C reactive protein. Scores run from 0 to 21 points. The tool separated patients who died from those who survived with good accuracy in both sets, with death rates near 32% and 30%. It was designed for quick, routine use.
Catalog record
| CREATOR | Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Gupta R, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, Nguyen-Van-Tam JS, Norman L, Noursadeghi M, Olliaro PL, Pritchard MG, Russell CD, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LC, Openshaw PJ, Baillie JK, Semple MG, Docherty AB, Harrison EM, ISARIC4C investigators. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score By Stephen R Knight, Antonia Ho, Riinu Pius, Iain Buchan, Gail Carson, Thomas M Drake, Jake Dunning, Cameron J Fairfield, Carrol Gamble, Christopher A Green, Rishi Gupta, Sophie Halpin Published in: The BMJ DOI: 10.1136/bmj.m3339 ABSTRACT Abstract Objective To develop and validate a pragmatic risk score to predict mortality in patients admitted to hospital with coronavirus disease 2019 (covid-19). Design Prospective observational cohort study. Setting International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study (performed by the ISARIC Coronavirus Clinical Characterisation Consortium—ISARIC-4C) in 260 hospitals across England, Scotland, and Wales. Model training was performed on a cohort of patients recruited between 6 February and 20 May 2020, with validation conducted on a second cohort of patients recruited after model development between 21 May and 29 June 2020. Participants Adults (age ≥18 years) admitted to hospital with covid-19 at least four weeks before final data extraction. Main outcome measure In-hospital mortality. Results 35 463 patients were included in the derivation dataset (mortality rate 32.2%) and 22 361 in the validation dataset (mortality rate 30.1%). The final 4C Mortality Score included eight variables readily available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea level, and C reactive protein (score range 0-21 points). The 4C Score showed high discrimination for mortality (derivation cohort: area under the receiver operating characteristic curve 0.79, 95% confidence interval 0.78 to 0.79; validation cohort: 0.77, 0.76 to 0.77) with excellent calibration (validation: calibration-in-the-large=0, slope=1.0). Patients with a score of at least 15 (n=4158, 19%) had a 62% mortality (positive predictive value 62%) compared with 1% mortality for those with a score of 3 or less (n=1650, 7%; negative predictive value 99%). Discriminatory performance was higher than 15 pre-existing risk stratification scores (area under the receiver operating characteristic curve range 0.61-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-0.73). Conclusions An easy-to-use risk stratification score has been developed and validated based on commonly available parameters at hospital presentation. The 4C Mortality Score outperformed existing scores, showed utility to directly inform clinical decision making, and can be used to stratify patients admitted to hospital with covid-19 into different management groups. The score should be further validated to determine its applicability in other populations. Study registration ISRCTN66726260 INTRODUCTION Disease resulting from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a high mortality rate with deaths predominantly caused by respiratory failure.1 As of 1 September 2020, over 25 million people had confirmed coronavirus disease 2019 (covid-19) worldwide and at least 850 000 people had died from the disease.2 3 As hospitals around the world are faced with an influx of patients with covid-19, there is an urgent need for a pragmatic risk stratification tool that will allow the early identification of patients infected with SARS-CoV-2 who are at the highest risk of death to guide management and optimise resource allocation. Prognostic scores attempt to transform complex clinical pictures into tangible numerical values. Prognostication is more difficult when dealing with a severe pandemic illness such as covid-19 because strain on healthcare resources and rapidly evolving treatments alter the risk of death over time. Early information has suggested that the clinical course of a patient with covid-19 is different from that of pneumonia, seasonal influenza, or sepsis.4 Most patients with severe covid-19 have developed a clinical picture characterised by pneumonitis, profound hypoxia, and systemic inflammation affecting multiple organs.1 A recent review identified many prognostic scores used for covid-19,5 which varied in their setting, predicted outcome measure, and the clinical parameters included. The large number of risk stratification tools reflects difficulties in their application, with most scores showing moderate performance at best and no benefit to clinical decision making.6 7 Many novel covid-19 prognostic scores have been found to have a high risk of bias, which could reflect development in small cohorts, and many have been published without clear details of model derivation and testing.5 Therefore, a risk stratification tool within a large national cohort of patients admitted to hospital with covid-19 is needed with clear development and validation details. Our aim was to develop and validate a pragmatic, clinically relevant risk stratification score that uses routinely available clinical information at hospital presentation to predict in-hospital mortality in patients admitted to hospital with covid-19. We then aimed to compare this score with existing prognostic models. METHODS Study design and setting The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study is an ongoing prospective cohort study. The study is being performed by the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC-4C) in 260 hospitals across England, Scotland, and Wales (National Institute for Health Research Clinical Research Network Central Portfolio Management System ID 14152). The protocol and further study details are available online.8 Model development and reporting followed the TRIPOD (transparent reporting of a multivariable prediction model for individual prediction or diagnosis) guidelines.9 The study is being conducted according to a predefined protocol (appendix 1). Participants The study recruited consecutive patients aged 18 years and older with a completed index admission to one of 260 hospitals in England, Scotland, or Wales.8 Reverse transcriptase polymerase chain reaction was the only mode of testing available during the period of study. The decision to test was at the discretion of the clinician attending the patient, and not defined by protocol. The enrolment criterion “high likelihood of infection” reflected that a preparedness protocol cannot assume a diagnostic test will be available for an emergent pathogen. In this activation, site training emphasised the importance of only recruiting proven cases. Data collection Demographic, clinical, and outcome data were collected by using a prespecified case report form. Comorbidities were defined according to a modified Charlson comorbidity index.10 Comorbidities collected were chronic cardiac disease, chronic respiratory disease (excluding asthma), chronic renal disease (estimated glomerular filtration rate ≤30), mild to severe liver disease, dementia, chronic neurological conditions, connective tissue disease, diabetes mellitus (diet, tablet, or insulin controlled), HIV or AIDS, and malignancy. These conditions were selected a priori by a global consortium to provide rapid, coordinated clinical investigation of patients presenting with any severe or potentially severe acute infection of public interest and enabled standardisation. Clinician defined obesity was also included as a comorbidity owing to its probable association with adverse outcomes in patients with covid-19.11 12 The clinical information used to calculate prognostic scores was taken from the day of admission to hospital.13 A practical approach was taken to sample size requirements.14 We used all available data to maximise the power and generalisability of our results. Model reliability was assessed by using a temporally distinct validation cohort with geographical subsetting, together with sensitivity analyses. Outcomes The primary outcome was in-hospital mortality. This outcome was selected because of the importance of the early identification of patients likely to develop severe illness from SARS-CoV-2 infection (a rule in test). We chose to restrict analysis of outcomes to patients who were admitted more than four weeks before final data